TRIVARX ORD
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX engages Beyond Drug Development to push Stabl-Im Phase 1 safety trial, targeting H2 2026 start and data for regulatory progress.
TrivarX Reports Strong US Veteran Trial Results Supporting Objective Depression Screening
TrivarX (ASX: TRI) has delivered positive results from a US-based clinical trial that demonstrate clinically meaningful, objective detection of current major depressive episodes in veterans using the company’s single-lead electrocardiogram technology.
TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]
TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes
An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode (cMDE). The algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart […]